CDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Conduit Pharmaceuticals's total equity for the quarter that ended in Sep. 2024 was $-9.12 Mil.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
The historical data trend for Conduit Pharmaceuticals's Total Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conduit Pharmaceuticals Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
Total Equity | -5.94 | -10.09 | -0.46 |
Conduit Pharmaceuticals Quarterly Data | |||||||||||
Dec21 | Mar22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Total Equity | Get a 7-Day Free Trial | -1.08 | -0.46 | -3.10 | -5.46 | -9.12 |
Total Equity and Total Liabilities are the two components for Total Assets.
Conduit Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as
Total Equity | = | Total Assets(Q: Dec. 2023 ) | - | Total Liabilities(Q: Dec. 2023 ) |
= | 7.224 | - | 7.681 | |
= | -0.46 |
Conduit Pharmaceuticals's Total Equity for the quarter that ended in Sep. 2024 is calculated as
Total Equity | = | Total Assets(Q: Sep. 2024 ) | - | Total Liabilities(Q: Sep. 2024 ) |
= | 2.993 | - | 12.111 | |
= | -9.12 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Regan | director, 10 percent owner | LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133 |
Intelmed Llc | other: See Responses | 11421 GOLDEN EAGLE COURT, NAPLES FL 34120 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
David Tapolczay | director, officer: Chief Executive Officer | 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU |
Faith L. Charles | director | ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019 |
Algo Holdings, Inc. | 10 percent owner, other: See Responses | 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309 |
Corvus Capital Ltd. | 10 percent owner, other: See Responses | WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107 |
Freda C Lewis-hall | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
James Bligh | director | 38 OXBERRY AVENUE, LONDON X0 SW6 5SS |
Shaolin Capital Management Llc | 10 percent owner | 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127 |
Richard Edward Feinberg | director | 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103 |
Murphy Canyon Acquisition Sponsor, Llc | 10 percent owner | 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123 |
Chele Chiavacci Farley | director | 4 RIDGE ROAD, TUXEDO PARK NY 10987 |
Bentzen Edwin H Iv | officer: Chief Accounting Officer | 2513 BIRCH HOLLOW ST, HENDERSON NV 89044 |
Jack Kendrick Heilbron | director, officer: CEO, President, and Chairman | 16433 BRONCO LANE, POWAY CA 92064 |
From GuruFocus
By Marketwired • 11-04-2024
By Marketwired • 10-11-2023
By Marketwired • 07-16-2024
By Marketwired • 08-12-2024
By Marketwired • 06-13-2024
By Marketwired • 09-22-2023
By GlobeNewswire • 11-01-2024
By Marketwired • 08-28-2024
By Marketwired • 11-19-2024
By Marketwired • 11-01-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.